publicado em 14/10/2012 às 13h57:00
   Dê o seu voto:

Serelaxina molecule reduces death rate from acute heart failure

Patients undergoing molecule showed a significant decrease in the occurrence of dyspnea or sensation of breathlessness

font size

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.

Results of new studies with the molecule serelaxina (RLX030) demonstrated a reduction in all cause-related death in patients with acute heart failure (AHF), a disease that has a higher mortality rate than most of the other cardiovascular disorders. The study will be presented to the medical profession during the congress American Heart Association in Los Angeles, USA, in November.

During the six months, the new molecule was shown to reduce significantly the occurrence of dyspnea or shortness of breath, the most common symptoms of ICA, and shows good tolerability among 1,161 patients from 11 countries who participated in the study. Inaugurating a new therapeutic class in cardiology, RLX030 is the first recombinant form of a human hormone called relexina-2, produced by men and especially for women during pregnancy to support the physiological changes of this period. The mechanism of action of serelaxina operates in the relaxation of blood vessels, leading to reduced stress on the heart and kidneys, in both men and women.

<b> ICA </ b>

Heart failure occurs when the heart is unable to supply enough blood to meet the body's needs. About half of patients with the disease die within an average period of five years after the diagnosis3, mainly due to acute episodes when symptoms suddenly worsen and the patient needs to be hospitalized urgently. The Acute Heart Failure (AHF) is a serious problem for health systems worldwide, responsible for approximately two million hospitalizations per year in Europe and the United Unidos4.

The IC has high prevalence and significant impact on morbidity and mortality worldwide, epidêmicas1 proportions. According to records, the average age of patients with acute HF is 72 to 73 years, 52% female. Data National Hospital Discharge Survey (NHDS) showed that between 1979 and 2004 hospitalizations for HF tripled, reaching nearly four million people in 2004 alone.

   Palavras-chave:   Heart failure    ICA    Serelaxina    Molecule    American Heart Association    Cardiovascular   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Serelaxina molecule reduces death rate from acute heart failure
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Serelaxina molecule reduces death rate from acute heart failure

Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Heart failure    ICA    serelaxina    molecule    American Heart Association    cardiovascular   
Leave your comment
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaú
Get the newsletter of the portal  iSaú
Recommend the portal iSaú
News from  iSaú in your blog or website.
Get news on the subject of your interest.
© 2000-2011 Todos os direitos reservados.